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Background: It remains unclear whether the 6-min walking test can predict performance
during stair-climbing in severe COPD patients. The present study aimed to assess different
pathophysiological changes between walking and stair-climbing in these patients.
Methods: Sixteen COPD patients (mean FEV1 33713% predicted) underwent a 6-min
walking test and performed stair-climbing (44 steps) in a randomized, cross-over design.
Blood gases, blood lactate, lung function parameters, maximal inspiratory mouth, sniff
nasal and twitch mouth pressures, blood pressure, heart rate, and Borg Dyspnea Scale
(BDS) were measured before and after exercise.
Results: The median drop of PaO2 during walking (2.6mmHg) and stair-climbing
(2.4mmHg) was comparable (p ¼ 0.93). However, stair-climbing caused more dyspnea
(median BDS 6.5 vs. 5.5, p ¼ 0.01), a higher median blood lactate (1.1 vs. 0.3mmol/l
po0.001), a more pronounced drop in mean pH (0.0570.02 vs. 0.0370.03, p ¼ 0.02)
and a higher increase in mean systolic blood pressure (27711 vs. 13716mmHg;
p ¼ 0.009). Stair-climbing, but not walking, caused prolonged lung hyperinflation (mean
TLC difference 4.474.7% predicted, p ¼ 0.003). There was no relationship between the
6-min walking distance (3147104m) and the time needed for stair-climbing (55733 s), nor
were there any differences in inspiratory muscle strength and heart rate.
Conclusion: Although the drop of PaO2 was comparable, stair-climbing resulted in more
prolonged hyperinflation of the lungs, higher blood lactate production and more dyspnea than
walking. The walking distance was not related to the time needed to manage stair-climbing.
Therefore, pathophysiological changes during the 6-min walking test do not anticipate
those during stair-climbing in patients with severe COPD.
& 2008 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Exercise in severe COPD 913Introduction Lung function, blood gas analysis and exerciseDyspnea and exercise limitation are the most troublesome
burdens endured by patients with chronic obstructive
pulmonary disease (COPD), progressing relentlessly as the
disease advances.1 In patients with severe COPD, daily
activities such as walking are associated with transient
oxygen desaturations.2,3 There are several tests that assess
exercise capacity and physiological changes during exertion
in patients with COPD. The most widely applied exercise
protocols are cardiopulmonary exercise testing and the
6-min walking test (6MWT).4 The 6MWT is often used to
assess exercise capacity in patients with respiratory dis-
eases.5,6 A recent study also suggested that the 6-min
walking distance (6MWD) is a good predictor of mortality in
COPD patients.7 However, patients with advanced COPD are
not only limited during walking but also during different
daily activities such as washing and eating.2 Furthermore,
stairs present a common daily obstacle, appearing in and
beyond the home. To date, only a few studies have
investigated COPD patients during stair-climbing.8,9 More-
over, it is still not clear if pathophysiological changes such as
exercise-induced oxygen desaturations are comparable
during walking and stair-climbing. It is particularly impor-
tant to ascertain this parameter in severe COPD patients
who face oxygen desaturations during exercise, since these
patients are at a high risk of death from cardiovascular
complications following exercise-induced hypoxia.10–12
Therefore, the present study aimed to assess the underlying
physiological differences between walking and stair-climbing
in severely progressed COPD patients.
Materials and methods
The study protocol was approved by the Institutional Review
Board for Human Studies of the Albert-Ludwigs University
Freiburg (Germany), and was performed in accordance with
the ethical standards laid down in the Declaration of
Helsinki. Written informed consent was obtained from
all subjects.
Patients
Stable stage III and IV COPD patients, classified according to
GOLD criteria13 and not being in a rehabilitation program
were included in this study. Patients were only assessed
if they already reported dyspnea during the mildest form
of exertion. Furthermore, all patients stated that their
exercise capacity was limited by dyspnea rather than by
skeletal muscle weakness. All patients received appropriate
medical therapy, according to GOLD guidelines; this in-
cluded inhaled, long-acting beta agonists, long-acting
anticholinergic agents and inhaled corticosteroids. Oral
theophylline was administered to six patients with severe
dyspnea despite optimal inhalative treatment as outlined
above. However, medication was not changed for the aims of
the study. Patients receiving oral steroids were excluded
from the study. Health-related quality of life (HRQL) using
the Severe Respiratory Insufficiency (SRI) Questionnaire14
was assessed in all patients at the time of inclusion in the
study.testing
Bodyplethysmography (Masterlab-Compact, Jaeger, Hoch-
berg, Germany) was performed according to the official
statement of the European Respiratory Society.15 Two
exercise tests were performed in a randomized cross-over
design within two consecutive days: a standardized
6MWT,16,17 and stair-climbing (44-step staircase located at
the hospital; step height, 0.16m). In patients receiving
supplemental oxygen during exercise the oxygen tank was
placed in a backpack. The following measurements were
taken both at rest and immediately after exercise: the
6MWD, the time for climbing all steps, dyspnea, as assessed
by a modified Borg Dyspnea Scale (BDS),18 blood gas
values taken from the arterialized ear lobe (cobas b221,
Roche, Mannheim, Germany), heart rate, blood pressure
(Sanoquell 329, Bosch&Sohn, Jungingen, Germany) and
blood lactate taken from the arterialized ear lobe (Super
GL, Hitado, Moehnensee, Germany). In addition, respiratory
muscle function was assessed before and after each exercise
test.
Tests on inspiratory muscle strength
Maximal static inspiratory mouth occlusion pressure sus-
tained for 1 s (PImax1.0) was measured at residual volume
using a spirometer with an integrated pressure transducer
(ZAN 100 Flowhandy II, ZAN GmbH, Oberthulba, Germany),
as described previously.19 Sniff nasal pressure (SnPna) was
recorded at functional residual capacity according to
previous recommendations20 using the same spirometer
and pressure transducer.
Twitch mouth pressure (TwPmo) during bilateral anterior
magnetic phrenic nerve stimulation (BAMPS, Magstim 200,2
Magstim Inc., Dyfed, Wales, UK)21,22 was measured in order
to provide data on non-volitionally assessed inspiratory
muscle strength. An inspiratory pressure trigger of 0.5 kPa
was used, and breathing frequency and tidal volume were
recorded as previously described in detail.23,24 A cut-off
value for TwPmo of 1.0 kPa was used to identify patients
with pathological inspiratory muscle strength.25 To avoid
twitch potentiation26–28 measurements were preceded by a
15min resting period in which the patient breathed quietly
without speaking. Additionally, the interval between two
magnetic stimulations exceeded 30 s.
Sequence of measurements
Measurements before and after exercise were performed
in the following standardized order: blood pressure,
heart rate, dyspnea, blood gases and blood lactate,
lung function, PImax, SnPna and TwPmo. The time span
between each of these measurements was also assessed
(Table 1).
Statistical analysis
Statistical analysis was performed using Sigma-Stat software
(Version 3.1, Systat Software, Inc., Point Richmond, CA,
USA). Unless otherwise stated, all data are presented
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parameter was defined as the difference in the change of
PaO2 when comparing walking and stair-climbing. The null-
hypothesis (H0) was defined as no difference in the change of
PaO2 between walking and stair-climbing. A sample size
determination (paired t-test, power 0.9, two-sided type I
error 0.05) was performed with an estimated SD of 10mmHg
for mean difference of PaO2-change, and a difference of at
least 10mmHg between walking and stair-climbing accord-
ing to previous findings.3 At least 13 subjects were needed in
each group for H0 rejection. Comparisons between walking
and stair-climbing were performed using the paired t-test/
Wilcoxon signed rank test for normally/non-normally dis-
tributed data. Subgroup analysis was performed in patients
either receiving or not receiving home mechanical ventila-
tion (HMV) for treatment of chronic hypercapnic respiratory
failure due to COPD; here, the unpaired t-test/Mann–
Whitney rank-sum test was used for normally/non-normally
distributed data. The 95% confidence interval of the mean
(95% CI) is given where appropriate.
Correlation analysis was performed using the Pearson
Product Moment Correlation for metric data. Linear regres-
sion analysis was performed where appropriate.29 A multiple
linear regression analysis was also performed both for
walking and stair-climbing, whereby BDS was used as the
dependent variable and changes in PaO2, PaCO2, blood
lactate and pH during exercise as independent variables.
Statistical significance was assumed with a p-value of
o0.05.Results
The following data, obtained from the complete group of
16 patients as well as the two subgroups, are presented
in Table 2: demographic and bodyplethysmographic data,
inspiratory muscle strength parameters and HRQL, as assessed
by the SRI summary scale. Four patients had known cardiovas-
cular co-morbidity: three with coronary heart disease and
one with dilative cardiomyopathy. However, cardiovascular co-
morbidity was not investigated per protocol. Eight patients
used nocturnal HMV for 18722 months; seven of these patients
underwent pressure-controlled ventilation and one received
pressure-supported ventilation. Mean inspiratory positive air-
way pressure was 3174mbar, mean expiratory positive airway
pressure was 471mbar, mean breathing frequency was
19.671.6/min. Eleven patients (eight with HMV) received
long-term oxygen therapy with a mean flow rate of 2.671.0 l
O2/min which remained unchanged during exercise. AllTable 1 Time span between each measurement.
Wa
End of exercise—bodyplethysmography 4
Bodyplethysmography—PImax, SnPna 5
PImax, SnPna—BAMPS 18
BAMPS ¼ bilateral anterior magnetic phrenic nerve stimulation, P
SnPna ¼ sniff nasal pressure.
n ¼ 12.patients managed to climb the 44 steps. Mean time needed
for stair-climbing was 55733 s. Mean 6MWD was 3147104m.
Changes in blood gases, lung function parameters and
inspiratory muscle strength during walking and stair-
climbing are presented in Table 3. While PaO2 decreased
during both types of exercise, there was no difference
between walking and stair-climbing with regard to the
primary outcome parameter, namely the PaO2 change
following exercise (p ¼ 0.93, Table 3). However, stair-
climbing caused more dyspnea, higher blood lactate values
and more acidosis compared to walking (Table 3). In
addition, stair-climbing, but not walking, caused lung
hyperinflation which was still detectable 5min after the
termination of exercises (Table 1). In contrast, both heart
rate and diastolic blood pressure increased during exercise,
but this did not differ between walking and stair-climbing
(p ¼ 0.69, 0.63, respectively). The increase of systolic blood
pressure was different between walking and stair-climbing
(13716 vs. 27711mmHg; p ¼ 0.009).
Linear regression analysis did not reveal a statistically
significant relationship between the 6MWD and the time
needed for stair-climbing. In contrast, the time needed for
stair-climbing was correlated with the decrease in PaO2
during walking (r ¼ 0.54; p ¼ 0.04) and stair-climbing
(r ¼ 0.60; p ¼ 0.02), as well as the increase in BDS during
stair-climbing (r ¼ 0.66; p ¼ 0.006). Furthermore, the SRI
Summary Scale was inversely correlated with the increase of
BDS during walking (r ¼ 0.57; p ¼ 0.03), but not during
stair-climbing (r ¼ 0.42; p ¼ 0.12). Following multiple
linear regression analysis, the decrease of PaO2 during
exercise emerged as the only predictor for BDS (walking
p ¼ 0.005; stair-climbing p ¼ 0.04), considering PaO2,
PaCO2, pH and blood lactate.
Figure 1 illustrates the differences between patients with
or without HMV in terms of the changes in PaO2 during
walking (10.7mmHg; 95% CI 3.3/18.1mmHg; p ¼ 0.008) and
stair-climbing (1.1mmHg; 95% CI 10.9/13.1mmHg;
p ¼ 0.85). No significant differences between these two
groups of patients were detected for changes in PaCO2
neither during walking nor stair-climbing (p40.05 in both
instances).
Patients with HMV displayed no differences in BDS score
changes following walking (6; interquartile range 4.5/7)
compared to those without HMV (3.5; interquartile range
1.5/7) (p ¼ 0.28) (Figure 2). In contrast, differences in BDS
score changes following stair-climbing in patients with
HMV (8; interquartile range 6.5/9.3) compared to those
without HMV (6 interquartile range 3.5/6.5) (p ¼ 0.021)
were statistically significant (Figure 2). The 6MWD waslking (min) Stair-climbing (min) p-Value
.471.2 5.071.4 0.25
.371.0 5.871.6 0.28
.375.8 18.375.6 0.60
Imax ¼ maximal static inspiratory mouth occlusion pressure,
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Table 2 Demographic data, lung function parameters and tests on inspiratory muscle strength prior to exercise testing in all
patients and subgroups comparing those with and without HMV.
Mean7SD Mean7SD Mean7SD p-Value
Group All Without HMV HMV
n 16 8 8
Male/female 11/5 5/3 6/2
COPDIII/COPDIV 5/11 5/3 0/8
Age (years) 59.277.2 57.377 62.675.9 0.12
BMI (kg/m2) 24.776.9 26.278.4 24.075.4 0.55
Pack years 44723 40728 50718 0.42
PaO2 (mmHg) at rest 64.578.7 62.275 65.9710.9 0.40
PaCO2 (mmHg) at rest 44.777.9 39.677 49.877.7 0.004
pH at rest 7.4170.03 7.4370.03 7.4070.02 0.03
FVC (%pred) 75.1719.7 64.8718.5 87.5715.6 0.02
FEV1 (%pred) 32.9712.6 28.2711.9 39.6710.6 0.06
FEV1/FVC (%) 35.5712.6 32.1715 39.979.6 0.24
TLC (%pred) 121.3722.8 119.4726.7 118.8716.2 0.94
RV (%pred) 239.8775.5 254.9790 209.6739.2 0.21
PImax1.0 (kPa) 5.471.8 4.871.8 6.171.7 0.14
SnPna (kPa) 4.871.5 4.271.1 5.771.4 0.04
TwPmo (kPa) 0.4070.19 0.370.1 0.570.2y 0.04
SRI-SS 59717z 60720 58715 0.80
%pred ¼ percent predicted from calculated normal value, BMI ¼ body mass index, COPDIII/IV ¼ stadium III/IV according GOLD criteria,
FEV1 ¼ forced expiratory volume in 1 s, FVC ¼ forced vital capacity, GOLD ¼ global initiative for chronic obstructive lung disease,
HMV ¼ home mechanical ventilation, PaCO2 ¼ arterial partial pressure of carbon dioxide, PaO2 ¼ arterial partial pressure of oxygen,
PImax1.0 ¼ maximal static inspiratory mouth occlusion pressure sustained for 1.0 s, RV ¼ residual volume, SD ¼ standard deviation,
SnPna ¼ sniff nasal pressure, SRI-SS ¼ Severe Respiratory Insufficiency Questionnaire Summary Scale, TLC ¼ total lung capacity,
TwPmo ¼ twitch mouth pressure after bilateral anterior magnetic phrenic nerve stimulation.
n ¼ 7.
yn ¼ 5.
zn ¼ 15.
Table 3 Changes (D) in blood gases, lung function parameters and inspiratory muscle strength during walking and stair-
climbing (n ¼ 16).
Walking Stair-climbing Difference (95% CI) p-Value
DPaO2 (mmHg) 2.6 2.4 nf 0.93
DPaCO2 (mmHg) 3.774.2 4.173.8 0.3673.4 (1.5/2.2) 0.69
DpH 0.0370.03 0.0570.02 0.0270.03 (0.03/0.0) 0.02
DBlood lactate (mmol/l) 0.33 1.14 nf o0.001
DFVC (%pred) 4.376.9 4.8713.6 0.5712.0 (7.2/6.2) 0.88
DFEV1
(%pred) 0.472.9 1.073.8 0.672.7 (0.9/2.1) 0.44
DTLC (%pred) 1.779.4 2.779.6 4.474.7 (1.8/7.0) 0.003
DRV (%pred) 0.2733.4 9.4733.6 9.673.5 (2.1/17.0) 0.016
DPlmax1.0 (kPa) 0.2471.1 0.0371.5 0.3/1.2 (0.9/0.4) 0.34
DSnPna (kPa) 0.271.1 0.171.0 0.371.0 (0.3/0.8) 0.29
DTwPmo (kPa)y 0.0670.2 0.0670.2 0.0170.2 (0.2/0.1) 0.93
DBDS 5.5 6.5 nf 0.01
D ¼ difference between pre- and post walking/stair-climbing, %pred ¼ percent predicted from calculated normal value, 95% CI ¼ 95%
confidence interval of the mean, BDS ¼ Borg Dyspnea Scale, difference ¼ difference between walking and stair-climbing,
FEV1 ¼ forced expiratory volume in 1 s, FVC ¼ forced vital capacity, nf ¼ normality test failed, PaCO2 ¼ arterial partial pressure of
carbon dioxide, PaO2 ¼ arterial partial pressure of oxygen, PImax1.0 ¼ maximal static inspiratory mouth occlusion pressure sustained
for 1.0 s, RV ¼ residual volume, SnPna ¼ sniff nasal pressure, TLC ¼ total lung capacity, TwPmo ¼ twitch mouth pressure during
bilateral anterior magnetic phrenic nerve stimulation.
n ¼ 15.
yn ¼ 10.
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Figure 1 Mean changes in PaO2 during walking and stair-climbing comparing patients with and without HMV. HMV ¼ home
mechanical ventilation, PaO2 ¼ arterial partial pressure of oxygen, t-bars represent 95% confidence interval of the mean.
Figure 2 Mean change in BDS-scores after walking and stair-climbing comparing patients with and without HMV. BDS ¼ modified
Borg Dyspnea Scale, HMV ¼ home mechanical ventilation, t-bars represent 95% confidence interval of the mean.
M. Dreher et al.916comparable (292790 vs. 3367118m; p ¼ 0.42), but time
needed for stair-climbing (71740 vs. 40712 s; p ¼ 0.053)
was different comparing patients with and without HMV with
almost reaching statistical significance.Discussion
The present study aimed to assess the differential effects of
walking and stair-climbing in severe COPD patients. The firstimportant finding arising from this study was that the overall
decline in PaO2 during walking and stair-climbing was
comparable. However, this study has also revealed major
physiological differences between walking and stair-climb-
ing in COPD patients, thus indicating that physiological
changes during the 6MWT do not predict those that
will occur during stair-climbing. Most importantly, stair-
climbing resulted in pronounced lung hyperinflation, blood
lactate production and dyspnea when compared to walking.
Furthermore, walking distance assessed by the 6MWT was
ARTICLE IN PRESS
Exercise in severe COPD 917not associated with the time needed for managing stair-
climbing.
The difference observed in lung hyperinflation is sug-
gested to be of clinical importance, since lung hyperinflation
has been shown to contribute greatly to the sensation of
dyspnea and exercise limitation.30 Stair-climbing, but not
walking, resulted in prolonged lung hyperinflation. It could
be argued that the time span between the termination of
exercise and bodyplethysmography was too long to detect
dynamic hyperinflation in this study. However, a previous
work identified early hyperinflaters with the onset of
dynamic hyperinflation at the beginning of exercise and
the offset lasting several minutes until complete reversion
after exercise termination.31 In contrast, late hyperinflaters
had only marginal changes in lung function at the end of
exercise and revealed no hyperinflation pattern after
exercise termination in this study.31 In line with this
reasoning, we have at least detected early hyperinflaters
in the present study. Therefore, strategies to prevent
dynamic hyperinflation are particularly important during
stair-climbing, which causes more lung hyperinflation than
walking.
The finding that stair-climbing resulted in more acidosis
compared to walking is explained by the observed increase
of blood lactate production, which is also supported by
the observation that changes in PaCO2 were equal for
both exercise modalities. Recently, it was shown in COPD
patients that walking resulted in less production of
blood lactate compared to that produced by cycling.32,33
Furthermore, COPD patients who developed contractile
fatigue of the quadriceps during cycle exercise had a
higher arterial lactate level during exercise when com-
pared to non-fatiguers.34 As clearly demonstrated in the
present study, simple walking causes less blood lactate
production, less dyspnea and a lower increase in systolic
blood pressure when compared to the effects of stair-
climbing; this confirms that walking is less exhausting
than other types of exertion in COPD patients. In addition,
there was a very low correlation between the decrease
in PaO2 during walking and the time needed for stair-
climbing. Moreover, there was no relationship between the
6MWD and the time needed for stair-climbing. All these
observations clearly demonstrate that the findings of the
6MWT cannot be extrapolated to other types of common
physical exertion, in particular, stair-climbing in COPD
patients.
The decline in PaO2 did not differ during stair-climbing
compared to walking. Therefore, the assessment of PaO2
during walking also provides information on what will
happen during stair-climbing. In addition, the decline in
PaO2 was predictive for developing dyspnea during both
types of exertion. Therefore, the prevention of a decline in
exercise-induced oxygen would be a likely means of
reducing dyspnea during both stair-climbing and walking.
In line with this, improved exercise capacity in patients with
severe COPD has been observed when the dosage of
supplemental oxygen is increased.35 However, this was only
true for non-hypercapnic COPD patients and a substantial
increase of PaCO2 has been shown even in patients with
marginal ventilatory insufficiency.35 Therefore, increasing
supplemental oxygen during exertion in hypercapnic COPD
patients might be disadvantageous due to increased carbondioxide retention. Non-invasive positive pressure ventilation
(NPPV) used for HMV applied during walking has previously
been shown to increase exercise ability, decrease dyspnea
under exertion and prevent exercise-induced oxygen decline
in patients with chronic hypercapnic respiratory failure due
to COPD.3 Therefore, future studies should address the
impact of NPPV during different types of exertion, e.g.
during stair-climbing, in patients with chronic hypercapnic
COPD.
Subgroup analysis revealed that patients receiving
HMV presented with more dyspnea during stair-climbing
and a stronger decline in oxygen during walking when
compared to patients without HMV. In addition, those
receiving HMV needed more time to manage stair-climbing.
Despite these differences in physical performance, patients
with HMV had comparable lung function parameters
and HRQL. In addition, inspiratory muscle strength was
clearly no worse than that of patients without HMV, and
changes in PaCO2 were also comparable between groups.
Nevertheless, exercise testing was capable of detecting
reduced physical performance in HMV patients, particularly
with regard to stair-climbing. This shows that physiological
parameters such as lung function, measurements of inspira-
tory muscle strength or HRQL cannot anticipate physical
performance, once HMV has been successfully established.
However, the number of patients in each group were
considerably small and the investigation of larger groups
of patients could have revealed differences also in other
parameters such as changes in PaCO2 following exercise.
Therefore, further studies are needed to clarify these
findings.
In conclusion, walking and stair-climbing lead to a
comparable decline in PaO2 in patients with severe COPD.
However, stair-climbing resulted in more pronounced hyper-
inflation of the lungs, higher blood lactate levels and
more dyspnea compared to walking. The walking distance
assessed by the 6MWT cannot predict the ability to manage
stair-climbing. Therefore, the physiological changes ob-
served in patients with severe COPD during the 6MWT do not
anticipate those that will be endured during stair-climbing.
Although the importance of the 6MWT in predicting long-
term prognosis is undisputed, it does not completely reflect
the burden of exercise limitations sustained by patients with
severe COPD.Conflict of interest statement
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